Nasdaq: **SXTP**

Market Data

60 Degrees Pharmaceuticals

Nasdaq: **SXTP**

Fiscal Year	Dec 31
Recent Price[1]	$0.26
Market Cap[1]	$2.9M
Shares Out.[1]	11.1M
Float[1]	8.1M
Avg. Vol. (90-day)[1]	584,814
Revenue (ttm)[2]	$0.2M
Cash (mrq)[2]	$2.2M

[1] As of March 12, 2024
[2] As of September 30, 2023

60degreespharma.com

Company Overview

60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P's pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.

Investment Highlights

ARAKODA® (tafenoquine) – Overview

- Safe, long-acting, mechanistically differentiated anti-malarial approved by FDA
- Discovered by and co-developed with U.S. Army
- 1,100+ patient exposures in 8+ published trials, weekly dosing for up to one year
- Commercially available in U.S. via network of major national distributors
- Existing commercial/regulatory infrastructure expected to facilitate cost-effective pathway to new/expanded indications following targeted clinical trials and label changes

ARAKODA Regimen of Tafenoquine - Research & Development Agenda

- Company has strong IP for malaria and other indications
- Preparing to launch a pivotal study of tafenoquine in hospitalized babesiosis patients in Q2 2024
- 47,000 cases of babesiosis (infections caused by red blood cell parasites similar to malaria that are transmitted by deer tick bites) occur in the US each year, and the incidence rate is increasing

60 Degrees Pharmaceuticals – Overview

- Seasoned Management Team and Board
- Profound clinical expertise in tafenoquine and related therapeutics
- Team has together led/managed four clinical trials
- Collectively led multiple pharmaceutical product approvals/ international pharmaceutical product launches
- Collectively led/provided guidance to multiple public & private entities
- Participated in/led multiple public listings

Anticipated Future Milestones

(Pivotal Babesiosis Study)



Other Anticipated Milestones:

- Detailed TAM Estimates for tick-borne diseases
- Hiring of Chief Commercial Officer
- Trade & Scientific Conferences
- New product development collaborations

Portfolio



NOTES:
*ARAKODA® is commercially available in the U.S. for malaria prevention and will be the subject of targeted marketing efforts in 2024, supported by the planned hiring of a commercial operations executive (pending). **Existing funds will support achieving FDA clearance. Proceeds from this offering if fully realized is anticipated to fund the Company through completion of randomization (first 30 patients) in this study, but its completion will require additional funds. *** Supported using existing funds, but project will only be initiated after sponsored research agreement is consummated. #Both these products have been the subject of clinical studies for other indications. Additional non-clinical efficacy and mechanism are required before committing to further clinical development. The yeast study will be funded using funds from this offering and will be initiated after consummation of a sponsored research agreement. The celgosivir project will be funded from proceeds of 60P share sales by a partner organization in the future (timeline TBD).

Value Proposition

60P is addressing the unmet medical need associated with infectious diseases through the development and commercialization of new small molecule therapeutics. By focusing on synthetic drugs (made by chemists in labs, excluding biologics) with good safety profiles based on prior clinical studies, 60P believes it has a cost-effective path to new indications that capitalizes on existing research to reduce costs and risk. 60P is expanding its commercialization efforts related to ARAKODA (tafenoquine), an antimalarial indicated for prophylaxis of malaria in patients 18 years and older and approved by the FDA in 2018. In Q2 2023, sales of ARAKODA increased by 150% relative to the same period in 2022, at an accelerating growth rate.

60P is implementing clinical research programs to evaluate the utility of the ARAKODA regimen of tafenoquine for non-malaria disease indications, with an upcoming planned pivotal study of tafenoquine in hospitalized babesiosis patients. 60P anticipates initiating patient enrollment for this trial in Q2 2024. According to Company estimates, 47,000 cases of babesiosis (infections caused by red blood cell parasites similar to malaria that are transmitted by deer tick bites) occur in the United States each year, and the incidence rate is increasing. Estimates are that 10% of Lyme disease patients are co-infected with babesiosis. 60P is also testing the viability of another product (Celgosivir) to determine whether to advance it into further clinical development and may seek to develop and license other molecules in the future.

About Babesiosis

- Tick-borne disease caused by protozoan parasites of the genus *Babesia*
- Invades red blood cells, causing:
  - Non-specific flu-like symptoms
  - Anemia
  - Death (1.6% mortality rate in hospitalized patients/10% in those with cardiac complications)
  - May be refractory to treatment in immunosuppressed patients
  - Associated with chronic post-treatment syndrome
- Common in Mid-West and Northeastern US
  - Geographic range expanding and incidence increasing
- Common coinfection with Lyme disease (10% of cases)